2017
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.Peer-Reviewed Original ResearchDisease-free survivalPhase III trialsIII trialsEGFR inhibitionMedian disease-free survivalRecurrent/metastatic diseaseErbB family blocker afatinibPre-planned interim analysisECOG PS 0Median treatment durationSquamous cell cancerDefinitive chemoradiationECOG PSEligible ptsAdvanced HNSCCConcurrent cisplatinN2 diseasePrimary endpointAdjuvant therapyMetastatic diseasePS 0Complete responseDisease recurrenceMedian ageNodal stage
2012
59IN Strategies to Optimize EGFR Therapies
Burtness B. 59IN Strategies to Optimize EGFR Therapies. Annals Of Oncology 2012, 23: ix42. DOI: 10.1016/s0923-7534(20)32673-9.Peer-Reviewed Original ResearchRecurrent/metastatic diseaseCombination of cetuximabCetuximab resistanceKinase inhibitorsMetastatic diseaseNeck cancerNuclear translocationInternational phase III trialReceptor tyrosine kinasesPhase III trialsSquamous cell carcinomaAugmentation of responsesDe novo resistanceH-ras mutationsMonoclonal antibody cetuximabTyrosine kinase inhibitorsK-ras mutationsFirst kinase inhibitorEpidermal growth factor receptorBristol-Myers SquibbGrowth factor receptorAdvanced headEGFR/HER2III trialsOral agents
2009
Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN)
Mehra R, Sherman E, Ruth K, Litwin S, Sylvester J, Tuttle H, Burtness B, Cohen R, Langer C. Phase II study of pemetrexed (P) and gemcitabine (G) in patients with advanced head and neck cancer (SCCHN). Journal Of Clinical Oncology 2009, 27: 6052-6052. DOI: 10.1200/jco.2009.27.15_suppl.6052.Peer-Reviewed Original ResearchPhase II studyResponse rateII studyOverall survivalMetastatic squamous cell cancerRecurrent/metastatic SCCHNRecurrent/metastatic diseaseStage 1Adequate bone marrowGrade 4 anemiaGrade 3 toxicityMedian overall survivalSquamous cell cancerLack of efficacyAdvanced HNSCCKarnofsky PSLA-SCCHNMetastatic SCCHNPrior therapyUnconfirmed PRAlternative regimenDefinitive therapyPrimary endpointRecurrent diseaseSecondary endpoints
2008
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology And Oncology 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.Peer-Reviewed Original ResearchConceptsRecurrent/metastatic diseaseRole of cetuximabSquamous cell carcinomaTreatment of HNSCCEpidermal growth factor receptorMetastatic diseaseCell carcinomaFirst-line regimenStandard of careGrowth factor receptorSurvival benefitSignificant morbidityCurable diseaseClinical trialsSingle agentDrug AdministrationCetuximabEGFR inhibitorsHNSCCBeneficial effectsDiseaseMonoclonal antibodiesFactor receptorCarcinomaFollowing review
2007
Advances in dendritic cell-based therapeutic vaccines for cervical cancer
Bellone S, Pecorelli S, Cannon MJ, Santin AD. Advances in dendritic cell-based therapeutic vaccines for cervical cancer. Expert Review Of Anticancer Therapy 2007, 7: 1473-1486. PMID: 17944571, DOI: 10.1586/14737140.7.10.1473.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlphapapillomavirusAnimalsAntigen PresentationAntigens, ViralCancer VaccinesClinical Trials as TopicCombined Modality TherapyDendritic CellsDisease ProgressionDNA-Binding ProteinsFemaleHumansMaleMiceNeoplasmsOncogene Proteins, ViralPapillomavirus E7 ProteinsPapillomavirus InfectionsPeptide FragmentsRepressor ProteinsT-Lymphocyte SubsetsUterine Cervical NeoplasmsConceptsCervical cancerDendritic cellsMetastatic diseaseTherapeutic vaccinesDendritic cell-based therapeutic vaccineE7 oncoproteinsPowerful antigen-presenting cellsRecurrent/metastatic diseasePrimary T cell responsesAutologous dendritic cellsInvasive cervical cancerHuman papillomavirus infectionT cell responsesTherapeutic clinical trialsTumor-specific target antigensAntigen-presenting cellsImportant risk factorImportant health problemNovel therapeutic strategiesPapillomavirus infectionRadical surgeryCervical dysplasiaCancer deathRisk factorsClinical trialsOverexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Bellone S, Frera G, Landolfi G, Romani C, Bandiera E, Tognon G, Roman JJ, Burnett AF, Pecorelli S, Santin AD. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. Gynecologic Oncology 2007, 106: 513-520. PMID: 17540437, DOI: 10.1016/j.ygyno.2007.04.028.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityCervical cancer cell linesPeripheral blood lymphocytesComplement-dependent cytotoxicityCancer cell linesEGFR-1Cervical cancerCervical tumorsRecurrent sitesPrimary cervical cancer cell linesCell linesRecurrent/metastatic diseaseTumor cell linesType 1 receptor expressionFlow cytometryFactor type 1 receptorMetastatic cervical cancerCervical cancer patientsType 1 receptorPresence of complementCervical tumor cell linesAttractive therapeutic strategyMetastatic diseaseCervical biopsiesMetastatic sites
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply